<DOC>
	<DOCNO>NCT00539500</DOCNO>
	<brief_summary>The goal clinical research study learn long take certain type transplant stem cell produce new blood cell . The safety treatment also study . Finally , researcher want learn collect cell CliniMACS device decrease possibility tumor cell contaminate ( appear ) stem cell reinfused participant .</brief_summary>
	<brief_title>Autologous Stem Cell Rescue With CD133+ Selected Cells High-Risk Neuroblastoma</brief_title>
	<detailed_description>Researchers want learn CD133+ select autologous stem cell transplant help control disease patient high-risk neuroblastoma . After cell collect , treat cell process lab use CliniMACS device . This device separate CD133+ cell . These select cell give back day transplant . If find eligible take part study , small plastic tube place collar bone area femoral vein ( groin area ) . This call central venous catheter ( CVC ) . You sign separate consent form CVC placement general anesthesia give . There may several week collection stem cell reinfusion cell high-dose chemotherapy . If CVC place femoral vein , CVC remove stem cell collect new CVC place collar bone admit stem cell transplant . The CVC use chemotherapy , fluid , blood product , stem cell , medication . The CVC remain longer need ( usually 2-3 month ) . To help move needed stem cell bone marrow blood , drug call G-CSF ( filgrastim ) inject skin . These injection may give day Days 2-7 . You caregiver taught give injection home . After 2 day filgrastim injection , blood sample ( 4 teaspoon time ) drawn day begin leukapheresis . This blood test use check number stem cell watch possible side effect . You instruct either continue daily injection stop . When number stem cell blood high enough , go MD Anderson Apheresis Unit stem cell collect . The procedure collect stem cell call leukapheresis . It similar donate platelet blood bank . For procedure , stem cell remove blood CVC , remain blood give back CVC . You one leukapheresis procedure per day , 1-5 day row , enough stem cell collect transplant . `` Back-up '' cell ( extra cell collect leukapheresis procedure ) also collect . These cell store cell processing lab may give back later white cell count recover . Each leukapheresis procedure take 4-6 hour . This research study use CliniMACS device process blood separate cell need transplantation . Researchers test small sample collected cell see tumor cell might present blood use CliniMACS device longer present process blood use device . Carboplatin etoposide design interfere growth cancer cell stop cell division , melphalan design damage DNA ( genetic material ) cell . The combination carboplatin , etoposide , melphalan cause large amount bone marrow cell die , stops blood cell produce normal . In order try restart production blood cell , autologous stem cell transplant often perform . For autologous transplant , stem cell remove blood . Usually stem cell collect , either give back patient collect , else small group cell certain `` marker '' cell surface select ( separate ) give back patient . The CliniMACS device machine process blood separate cell need transplantation . The CliniMACS device design select stem cell different marker cell surface normally select . The marker call CD133+ , researcher believe transplant cell marker make infused cell less likely contaminate neuroblastoma cell , compare standard method cell selection . After 5 day leukapheresis procedure , number stem cell collect low certain level , longer eligible take part study . Before start treatment study , `` screening test . '' These test help doctor decide eligible take part study . If test perform recently , may need repeat . To check status disease , CT scan , bone marrow aspiration biopsy , chest x-ray . The CT scan perform chest , abdomen , pelvis ( need , brain ) . To collect bone marrow biopsy , area hip chest bone numb anesthetic , small amount bone marrow bone withdrawn large needle . You pulmonary function test ( measure lung function ) , echocardiogram ( measure heart function ) , electrocardiogram ( EKG -- test measure electrical activity heart ) . You physical exam , include measurement vital sign ( blood pressure heart rate ) , height , weight . Blood ( 4 tablespoon ) draw routine test check disease hepatitis HIV . Females able child must negative urine pregnancy test . You also 12 24-hour urine test carboplatin give . For test , collect urine 12 24 hour . You provide container collect urine . This test use help decide dose carboplatin receive . After enough stem cell collect , time decide upon neuro-oncologist transplantation doctor , admit hospital receive fluid chemotherapy drug carboplatin , etoposide , melphalan , accord standard schedule . After chemotherapy , 3 `` rest '' day chemotherapy give . On day third rest day , stem cell infuse back CVC . To help speed recovery white blood cell , drug call filgrastim inject skin . You receive filgrastim injection skin day , white blood cell count recovers ( usually 2-3 week ) . You may also receive standard antibiotic , fluid , and/or medication , doctor feel necessary base symptom may . While hospital , physical exam day . Blood ( 4 teaspoon time ) draw 3-7 day per week , blood count fully recover side effect chemotherapy resolve . At time , able leave hospital . From time leave hospital Day 60 , follow-up visit least per week . At visit , physical exam . Blood ( 4 teaspoon time ) drawn routine test . However , participation study annual follow-up time medical history physical exam , blood ( 4 teaspoon ) draw routine test , CT scan . If disease get bad intolerable side effect occur time study , take study . This investigational study . All drug use study commercially available FDA approve use neuroblastoma . The CliniMACS device commercially available FDA approve . It authorize use research . Up 20 patient take part study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Newly diagnose highrisk Neuroblastoma define : a. INSS 2A/2B old 365 day MYCN amplify , unfavorable histology , ploidy . b. INSS Stage 3 , old 365 day MYCN amplification and/or unfavorable histology . c. INSS Stage 4 4S , less 365 day age , MYCN amplification d. INSS Stage 4 , 365 , regardless MYCN amplification histology . 2 . Pretransplant modality may include surgery , chemotherapy , radiation therapy . Radiation must include lung field . Only patient CR , PR primary site eligible . 3 . Any recurrent neuroblastoma least partial response salvage therapy . 4 . Lansky performance score great equal 50 patient &lt; /= 16 year age , Zubrod performance status score 02 patient &gt; 16 year age . 5 . No symptomatic pulmonary disease . FEV1 , FVC , DLCO &gt; /= 50 % expect corrected hemoglobin . If unable perform pulmonary function test ( child &lt; 6 year age ) , pulse oximetry &gt; /= 92 % room air . 6 . Adequate cardiac function demonstrate leave ventricular ejection fraction &gt; /= 50 % echocardiogram . 7 . Adequate hepatic function define SGOT ( AST ) SGPT ( ALT ) &lt; 5 X upper limit normal . 8 . All patient and/or parent legal guardian must sign write informed consent . 9 . Females childbearing potential define postmenopausal 12 month previous surgical sterilization must negative urine pregnancy test within 30 day register . Patients inform risk use adequate contraception . 1 . Patient pregnant breastfeeding . 2 . Active infection control antibiotic seven day therapy . 3 . Brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>ClinicMACS</keyword>
	<keyword>CliniMACS</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>CD133+ Cells</keyword>
</DOC>